Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHS-388 in Advanced Solid Tumors
NCT04374877Phase 1Completed
- Start
- Apr 2020
- Primary completion
- May 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label trial of casdozokitug in solid tumor, clear cell renal cell carcinoma (ccRCC), hepatocellular carcinoma (HCC) and 1 more (4 arms). Primary endpoints: Dose Limiting Toxicity at 21 days, Objective Response Rate up to 24 months and 1 more. Started Apr 2020; status: completed.
02
Drugs
casdozokitug
03
Conditions
solid tumorclear cell renal cell carcinoma (ccRCC)hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04374877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374877.